Category: Company News

Genentech has received FDA Priority Review for Gazyva in primary membranous nephropathy, bringing the therapy closer to potentially becoming the first FDA-approved treatment for the rare autoimmune kidney disease. Key Investor Takeaways Why RHHBY Stock Is in Focus Genentech, a member of the Roche Group (USOTC:RHHBY), announced that the U.S. Food and Drug Administration has…

Xeriant has secured a U.S. patent covering its proprietary fire-resistant composite technology, strengthening the intellectual property behind its NEXBOARD construction materials platform and supporting future commercialization efforts. Key Investor Takeaways Why XERI Stock Is in Focus Xeriant (USOTC:XERI) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,679,047 covering the company’s…

BioAdaptives has introduced XcellaraHeart™, a new cardiovascular wellness supplement built on its Xcellara™ platform, with commercial availability scheduled to begin on August 1, 2026. Key Investor Takeaways Why BDPT Stock Is in Focus BioAdaptives (USOTC:BDPT) announced the upcoming commercial launch of XcellaraHeart™, a cardiovascular wellness formula designed to combine its existing Xcellara™ stem/progenitor cell mobilization…

Victory Marine Holdings reported a significant reduction in convertible debt alongside continued commercialization of its beverage and wellness platform, marking the first full quarter of execution following its March 2026 reverse merger. Key Investor Takeaways Why VMHG Stock Is in Focus Victory Marine Holdings (USOTC:VMHG), through its operating subsidiary Dunn & Groux Beverage Holdings, highlighted…

Cardiff Oncology has secured a $10 million registered direct offering, providing additional capital for working capital and general corporate purposes as the company continues advancing its lead oncology program. Key Investor Takeaways Why CRDF Stock Is in Focus Cardiff Oncology (NASDAQ:CRDF) announced definitive agreements for a registered direct offering expected to generate approximately $10 million…

Rekor Systems’ preliminary second-quarter results point to stronger operating performance following a broad restructuring effort, while management now expects to reach Adjusted EBITDA profitability during the second half of 2026. Key Investor Takeaways Why REKR Stock Is in Focus Rekor Systems (NASDAQ:REKR) reported preliminary, unaudited second-quarter 2026 financial results that suggest meaningful progress in its…

The milestone payment strengthens VivoSim’s cash position while management projects significant revenue growth driven by expanding demand for its human-based preclinical testing platform. Key Investor Takeaways Why VIVS Stock Is In Focus The key catalyst is VivoSim’s announcement that it has received a $5 million milestone payment from Eli Lilly related to an inflammatory bowel…

VSee Health (NASDAQ:VSEE) highlighted its strategy to position its enterprise telehealth platform as the infrastructure layer for artificial intelligence adoption across hospitals, while pointing to continued growth in its healthcare network and enterprise business. Key Investor Takeaways Why VSEE Stock Is in Focus VSee Health outlined its long-term strategy for integrating artificial intelligence into its…

Ameerex Corporation (USOTC:HIRU) outlined progress across its North American resource program and Patagonia Lithium joint venture while also providing updates on its ongoing audit, legal proceedings, and a potential share buyback initiative. Key Investor Takeaways Why HIRU Stock Is in Focus Ameerex provided an operational update covering multiple strategic initiatives across its resource portfolio. The…

Ensysce Biosciences (NASDAQ:ENSC) has received a $5.3 million award from the National Institute on Drug Abuse (NIDA), completing a multi-year federal grant totaling $15.1 million to support development of its Breakthrough Therapy-designated opioid candidate PF614-MPAR. Key Investor Takeaways Why ENSC Stock Is in Focus Ensysce announced it has received a Notice of Award for $5.3…